Fabrice Egros - 18 May 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
18 May 2021
Net transactions value
-$154,654
Form type
4
Filing time
20 May 2021, 16:46:20 UTC
Next filing
20 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $85,867 +11,926 +75% $7.20 27,926 18 May 2021 Direct
transaction SNDX Common Stock Options Exercise $13,262 +1,683 +6% $7.88 29,609 18 May 2021 Direct
transaction SNDX Common Stock Sale $222,398 -11,926 -40% $18.65 17,683 18 May 2021 Direct F1
transaction SNDX Common Stock Sale $31,385 -1,683 -9.5% $18.65 16,000 18 May 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -1,683 -100% $0.000000* 0 18 May 2021 Common Stock 0 $7.88 Direct F2
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -11,926 -100% $0.000000* 0 18 May 2021 Common Stock 0 $7.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 93,317 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested.
F2 This option is fully vested.